
浏览全部资源
扫码关注微信
上海中医药大学附属龙华医院耳鼻喉科,上海 200032
主治医生,硕士。研究方向:变应性鼻炎及耳鸣的基础与临床。E-mail:jfdbj3@sina.com
主任医师,博士。研究方向:鼻部炎症与免疫机制的基础与临床。E-mail:juanitohuan@163.com
收稿:2026-02-06,
修回:2026-07-07,
录用:2026-07-09,
网络首发:2026-07-24,
纸质出版:2026-07-30
移动端阅览
兰家辉,张弢,董伟,等.基于MAPK/STAT3通路探讨人参皂苷F1对变应性鼻炎的改善作用及机制 [J].中国药房,2026,37(14):1845-1850.
LAN Jiahui,ZHANG Tao,DONG Wei,et al.Improvement effect and mechanism of ginsenoside F1 on allergic rhinitis rats based on the MAPK/STAT3 pathway[J].ZHONGGUO YAOFANG,2026,37(14):1845-1850.
兰家辉,张弢,董伟,等.基于MAPK/STAT3通路探讨人参皂苷F1对变应性鼻炎的改善作用及机制 [J].中国药房,2026,37(14):1845-1850. DOI: 10.6039/j.issn.1001-0408.2026.14.08.
LAN Jiahui,ZHANG Tao,DONG Wei,et al.Improvement effect and mechanism of ginsenoside F1 on allergic rhinitis rats based on the MAPK/STAT3 pathway[J].ZHONGGUO YAOFANG,2026,37(14):1845-1850. DOI: 10.6039/j.issn.1001-0408.2026.14.08.
目的
2
基于丝裂原激活的蛋白激酶(MAPK)/信号转导及转录活化因子3(STAT3)通路探讨人参皂苷F1(GF1)对变应性鼻炎(AR)大鼠的改善作用及潜在机制。
方法
2
将雄性SD大鼠分为对照组(15只)和造模组(55只),其中造模组大鼠采用卵白蛋白基础致敏+局部激发的方式构建AR大鼠模型。将造模成功的大鼠随机分为AR组、低剂量GF1组[2.5 mg/(kg·d)]、高剂量GF1组[5 mg/(kg·d)]、氯雷他定组[阳性对照,1.5 mg/(kg·d)]、高剂量GF1+MAPK激活剂组[5 mg/(kg·d)GF1+0.2 nmol C16-PAF],每组10只;另从对照组中随机选取大鼠10只,作为空白对照组。各组大鼠经鼻腔滴注或(和)灌胃相应药液或生理盐水,每天1次,连续28 d。末次给药后,观察大鼠AR症状并进行鼻炎症状评分,观察其鼻黏膜组织病理改变,检测其鼻腔灌洗液中炎症细胞数量,血清中炎症因子[白细胞介素4(IL-4)、IL-17、γ干扰素(IFN-γ)]和免疫球蛋白E(IgE)水平,鼻腔黏膜组织中杯状细胞密度、肥大细胞数量以及MAPK/STAT3通路相关蛋白的表达情况。
结果
2
与空白对照组比较,AR组大鼠鼻黏膜组织上皮层病理损伤明显,可见间质水肿、炎症细胞浸润等病理改变;其鼻炎症状评分,巨噬细胞、淋巴细胞、嗜酸性粒细胞、中性粒细胞、肥大细胞数量和杯状细胞密度,IL-4、IL-17、IgE水平,以及p38 MAPK、STAT3蛋白的磷酸化水平均显著升高或增加,IFN-γ水平显著降低(
P
<0.05)。与AR组比较,各药物组大鼠鼻黏膜组织上皮层病理损伤均有所恢复,各定量指标均显著改善,且高剂量GF1组、氯雷他定组的改善均较低剂量GF1组显著(
P
<0.05);C16-PAF可显著逆转GF1对各定量指标的改善作用(
P
<0.05)。
结论
2
GF1可改善AR大鼠的鼻炎症状,减轻鼻黏膜组织炎症反应;上述作用可能与其抑制MAPK/STAT3通路激活有关。
OBJECTIVE
2
To explore the improvement effect and potential mechanism of ginsenoside F1 (GF1) on allergic rhinitis (AR) rats based on the mitogen-activated protein kinase (MAPK)/signal transducer and activator of transcription 3 (STAT3) pathway.
METHODS
2
Male SD rats were divided into a control group (
n
=15) and a modeling group (
n
=55). The AR rat model was established by basic sensitization with ovalbumin followed by local challenge. The successfully modeled rats were randomly assigned to the AR group, low-dose GF1 group [2.5 mg/(kg·d)
]
, high-dose GF1 group [5 mg/(kg·d)
]
, loratadine group (positive control, 1.5 mg/(kg·d)
]
, and high-dose GF1+MAPK activator group [5 mg/(kg·d) GF1+0.2 nmol C16-PAF
]
, with 10 rats in each group. Another 10 rats from the control group were randomly selected as the blank control group. Rats in each group received corresponding drug solutions or normal saline via intranasal instillation and/or oral gavage once daily for 28 consecutive days. After the final administration, AR symptoms were observed and rhinitis symptom scores were assessed. Histopathological changes of the nasal mucosa were examined. The number of inflammatory cells in nasal lavage fluid, serum levels of inflammatory cytokines [interleukin-4 (IL-4), IL-17, interferon-γ (IFN-γ)
]
and immunoglobulin E (IgE), as well as the density of goblet cells, the number of mast cells, and the expression of MAPK/STAT3 pathway-related proteins in nasal mucosal tissues were measured.
RESULTS
2
Compared with the blank control group, the AR group exhibited marked pathological damage to the nasal mucosal epithelium, characterized by interstitial edema and inflammatory cell infiltration. The rhinitis symptom score, the number of macrophages, lymphocytes, eosinophils, neutrophils and mast cells, the density of goblet cells, the levels of IL-4, IL-17 and IgE, as well as the protein phosphorylation levels of p38 MAPK and
STAT3 were significantly increased or elevated, while the level of IFN-γ was significantly decreased in the AR group (
P
<0.05). Compared with the AR group, all administration groups showed recovery of nasal mucosal epithelial pathological damage and significant improvements in all quantitative indicators, with the high-dose GF1 group and loratadine group showing more pronounced improvements than the low-dose GF1 group (
P
<0.05). C16-PAF significantly reversed the ameliorative effects of GF1 on all quantitative indicators (
P
<0.05).
CONCLUSIONS
2
GF1 can alleviate rhinitis symptoms in AR rats and inhibit inflammatory responses, which may be related to the inhibition of the MAPK/STAT3 pathway activation.
Hao Y , Yang Y J , Zhao H F , et al . Multi-omics in allergic rhinitis:mechanism dissection and precision medicine [J ] . Clin Rev Allergy Immunol , 2025 , 68 ( 1 ): 19 .
Yuan Y Z , Wang C , Wang G Q , et al . Airway microbiome and serum metabolomics analysis identify differential candidate biomarkers in allergic rhinitis [J ] . Front Immunol , 2021 , 12 : 771136 .
Iordache A , Boruga M , Mușat O , et al . Relationship between allergic rhinitis and allergic conjunctivitis(allergic rhinoconjunctivitis):review [J ] . Rom J Ophthalmol , 2022 , 66 ( 1 ): 8 - 12 .
Cong J C , Lv H , Xu Y . The role of nociceptive neurons in allergic rhinitis [J ] . Front Immunol , 2024 , 15 : 1430760 .
Cohen B . Allergic rhinitis [J ] . Pediatr Rev , 2023 , 44 ( 10 ): 537 - 550 .
Wise S K , Damask C , Roland L T , et al . International consensus statement on allergy and rhinology:allergic rhinitis:2023 [J ] . Int Forum Allergy Rhinology , 2023 , 13 ( 6 ): 473 - 767 .
Liu T , Zhang R , Jiang L Y , et al . The potential application and molecular mechanisms of natural products in the treatment of allergic rhinitis:a review [J ] . Phytomedicine , 2024 , 129 : 155663 .
Zhang Y , Ma J L , Liu S , et al . Ginsenoside F1 attenuates pirarubicin-induced cardiotoxicity by modulating Nrf2 and AKT/Bcl-2 signaling pathways [J ] . J Ginseng Res , 2023 , 47 ( 1 ): 106 - 116 .
Kim S J , Lee J , Choi W S , et al . Ginsenoside F1 attenuates eosinophilic inflammation in chronic rhinosinusitis by promoting NK cell function [J ] . J Ginseng Res , 2021 , 45 ( 6 ): 695 - 705 .
Zhang M Y , Sun X W , Yu X , et al . Limosilactobacillus reuteri regulates gut microbiota and increases the effective metabolite luteolin to inhibit MAPK/STAT3 signaling pathway to alleviate allergic rhinitis [J ] . Front Microbiol , 2025 , 16 : 1522191 .
雷西熙 , 邓可斌 , 姜锐 . 槲皮素通过TLR4/IRAK4/NF-κB信号通路对过敏性鼻炎大鼠炎症反应的影响 [J ] . 中国药房 , 2025 , 36 ( 7 ): 832 - 836 .
刘顺利 , 粱萌萌 , 刘大英 , 等 . 玉屏风颗粒通过调控TLR9/AP-1信号通路对过敏性鼻炎大鼠鼻黏膜重塑、白三烯水平及免疫调节的作用 [J ] . 中国老年学杂志 , 2024 , 44 ( 5 ): 1188 - 1192 .
院金烨 , 闫莹 , 牟艳芳 , 等 . 荆防颗粒对寒湿型过敏性鼻炎大鼠的保护作用及其机制探讨 [J ] . 世界中医药 , 2025 , 20 ( 9 ): 1513 - 1519 .
周丹 , 金发光 , 潘蕾 , 等 . 胡黄连苷Ⅱ通过抑制NF-κB/MAPK信号通路减轻过敏性哮喘大鼠炎症反应 [J ] . 现代生物医学进展 , 2024 , 24 ( 10 ): 1818 - 1824,1868 .
王金凤 , 王枫 , 赵桂芝 , 等 . 小青龙汤对过敏性鼻炎大鼠Th1/Th2细胞因子失衡及SP、Annexin1、VCAM-1表达的影响 [J ] . 现代中西医结合杂志 , 2022 , 31 ( 15 ): 2051 - 2057 .
刘曦 , 罗晓松 , 孙涛 . 人参皂苷Rb 1 对过敏性哮喘大鼠炎症反应、免疫功能及JAK2/STAT3信号通路的影响 [J ] . 中国老年学杂志 , 2024 , 44 ( 2 ): 367 - 371 .
Zoabi Y , Levi-Schaffer F , Eliashar R . Allergic rhinitis:pathophysiology and treatment focusing on mast cells [J ] . Biomedicines , 2022 , 10 ( 10 ): 2486 .
Zhang X , Zhang Z Q , Peng Q , et al . The immunogenetic landscape of allergic rhinitis:from cellular effectors to gene regulation and targeted therapies [J ] . Int J Biol Sci , 2026 , 22 ( 3 ): 1322 - 1345 .
Zhu X J , Cheng F L , Duan H Y , et al . Novel insights into the study of goblet cell hypersecretion in allergic rhinitis [J ] . Front Immunol , 2025 , 16 : 1525928 .
程杰 , 王文广 . 川芎嗪调节MCP-1对过敏性鼻炎大鼠的免疫调节作用研究 [J ] . 医学分子生物学杂志 , 2025 , 22 ( 3 ): 259 - 265 .
陈艳春 , 徐世影 , 应航宇 , 等 . 防风水提物对抗生素加重小鼠过敏性鼻炎的改善作用研究 [J ] . 浙江医学 , 2023 , 45 ( 5 ): 453 - 459 .
李灿灿 , 邱建利 . 探讨血清总IgE联合中性粒细胞/淋巴细胞比值在过敏性鼻炎诊断中的应用价值 [J ] . 四川中医 , 2025 , 43 ( 9 ): 118 - 123 .
Guo L P , Yan M , Niu R B , et al . Role of Th2,Th17 and Treg cells and relevant cytokines in pathogenesis of al-lergic rhinitis [J ] . Allergy Asthma Clin Immunol , 2024 , 20 ( 1 ): 40 .
Yang M L , Sun L W , Zhu D D , et al . Recent advances in understanding the effects of T lymphocytes on mucosal barrier function in allergic rhinitis [J ] . Front Immunol , 2023 , 14 : 1224129 .
田波 , 陈颖 , 潘红玲 , 等 . 基于TLR4/NF-κB通路探究百里香酚对过敏性鼻炎模型大鼠鼻黏膜病理学及免疫功能的影响 [J ] . 中国老年学杂志 , 2025 , 45 ( 5 ): 1203 - 1208 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621